Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Drug regulator to probe Ranbaxy Laboratories Ltd's records, approvals in India-Business Standard


Tuesday, 21 May 2013 10:58am EDT 

Business Standard reported that Ranbaxy Laboratories Ltd has just managed to settle long-pending issues with the US Department of Justice after agreeing to pay a hefty penalty of $500 million. The health ministry has now ordered the Drugs Controller General of India (DCGI) to conduct a detailed probe and examination of all the dossiers and drug applications filed by the company in past on the basis of which approvals were granted to it, a source in the health ministry said. The DCGI is expected to submit a report within a month, after which the ministry will decide on the future course of action.